Viridian Therapeutics, Inc.
VRDN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1,140,677 | $1,096,519 | $1,534,599 |
| - Cash | $169,647 | $117,324 | $116,215 | $99,594 |
| + Debt | $23,090 | $21,341 | $21,221 | $21,095 |
| Enterprise Value | – | $1,044,694 | $1,001,525 | $1,456,100 |
| Revenue | $70,570 | $75 | $72 | $72 |
| % Growth | 93,993.3% | 4.2% | 0% | – |
| Gross Profit | $70,570 | $75 | $72 | $72 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$33,929 | -$100,108 | -$86,209 | -$78,744 |
| % Margin | -48.1% | -133,477.3% | -119,734.7% | -109,366.7% |
| Net Income | -$34,599 | -$100,735 | -$86,912 | -$79,725 |
| % Margin | -49% | -134,313.3% | -120,711.1% | -110,729.2% |
| EPS Diluted | -0.34 | -1 | -0.87 | -0.81 |
| % Growth | 66% | -14.9% | -7.4% | – |
| Operating Cash Flow | -$84,611 | -$75,373 | -$92,653 | -$73,332 |
| Capital Expenditures | -$127 | -$42 | -$86 | -$114 |
| Free Cash Flow | -$84,738 | -$75,415 | -$92,739 | -$73,446 |